{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:14:59Z","timestamp":1788322499284,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01918-2","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:30:15Z","timestamp":1788319815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BioPROTACs: a promising approach for targeted protein degradation"],"prefix":"10.1038","author":[{"given":"Yu-yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-ru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-shuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-ling","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-wei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-ang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-xin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-bo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1918_CR1","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1021\/acs.accounts.5c00003","volume":"58","author":"SP He","year":"2025","unstructured":"He SP, Dong GQ, Sheng CQ. Strategies for precise modulation of protein degradation. Acc Chem Res. 2025;58:1236\u201348.","journal-title":"Acc Chem Res"},{"key":"1918_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16:101\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"1918_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","volume":"25","author":"M Hinterndorfer","year":"2025","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE. Targeted protein degradation for cancer therapy. Nat Rev Cancer. 2025;25:493\u2013516.","journal-title":"Nat Rev Cancer"},{"key":"1918_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60039-2","volume":"16","author":"RX Ge","year":"2025","unstructured":"Ge RX, Chen M, Wu SJ, Huang SR, Zhou P, Cao MH, et al. DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases. Nat Commun. 2025;16:4683.","journal-title":"Nat Commun"},{"key":"1918_CR5","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/s41401-025-01538-2","volume":"46","author":"RX Ge","year":"2025","unstructured":"Ge RX, Chen M, Li QC, Liu M, Zhou J, Xie SB. Targeting neurodegenerative disease-associated protein aggregation with proximity-inducing modalities. Acta Pharmacol Sin. 2025;46:2337\u201346.","journal-title":"Acta Pharmacol Sin"},{"key":"1918_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202515852","volume":"13","author":"MX Li","year":"2026","unstructured":"Li MX, Yue Y, Wu SJ, He XY, Song JY, Ma SW, et al. DNA nanoflower LYTACs enable efficient VEGF degradation and verteporfin loading for combined therapy of wet age-related macular degeneration. Adv Sci. 2026;13:e15852.","journal-title":"Adv Sci."},{"key":"1918_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115839","volume":"261","author":"J Song","year":"2023","unstructured":"Song J, Hu MZ, Zhou J, Xie SB, Li TL, Li Y. Targeted protein degradation in drug development: recent advances and future challenges. Eur J Med Chem. 2023;261:115839.","journal-title":"Eur J Med Chem"},{"key":"1918_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.tips.2023.05.008","volume":"44","author":"ZH Yang","year":"2023","unstructured":"Yang ZH, Pang QX, Zhou J, Xuan CH, Xie SB. Leveraging aptamers for targeted protein degradation. Trends Pharmacol Sci. 2023;44:776\u201385.","journal-title":"Trends Pharmacol Sci."},{"key":"1918_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.31255","volume":"239","author":"RS Zhang","year":"2024","unstructured":"Zhang RS, Xie SB, Ran J, Li T. Restraining the power of proteolysis targeting chimeras in the cage: a necessary and important refinement for therapeutic safety. J Cell Physiol. 2024;239:e31255.","journal-title":"J Cell Physiol"},{"key":"1918_CR10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1021\/acs.jmedchem.2c01557","volume":"66","author":"M Chen","year":"2023","unstructured":"Chen M, Zhou P, Kong Y, Li JR, Li Y, Zhang Y, et al. Inducible degradation of oncogenic nucleolin using an aptamer-based PROTAC. J Med Chem. 2023;66:1339\u201348.","journal-title":"J Med Chem"},{"key":"1918_CR11","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/j.scib.2024.05.017","volume":"69","author":"LP Kong","year":"2024","unstructured":"Kong LP, Meng FL, Zhou P, Ge RX, Geng XS, Yang ZH, et al. An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer. Sci Bull. 2024;69:2122\u201335.","journal-title":"Sci Bull"},{"key":"1918_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1191","volume":"13","author":"LP Kong","year":"2023","unstructured":"Kong LP, Meng FL, Wu SJ, Zhou P, Ge RX, Liu M, et al. Selective degradation of the p53-R175H oncogenic hotspot mutant by an RNA aptamer-based PROTAC. Clin Transl Med. 2023;13:e1191.","journal-title":"Clin Transl Med"},{"key":"1918_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57823-5","volume":"16","author":"ZH Yang","year":"2025","unstructured":"Yang ZH, Chen M, Ge RX, Zhou P, Pan W, Song JY, et al. Identification of a non-inhibitory aptameric ligand to CRL2ZYG11B E3 ligase for targeted protein degradation. Nat Commun. 2025;16:2494.","journal-title":"Nat Commun"},{"key":"1918_CR14","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.7150\/thno.98467","volume":"14","author":"P Zhou","year":"2024","unstructured":"Zhou P, Zhang S, Li L, Zhang RS, Guo GZ, Zhang YF, et al. Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis. Theranostics. 2024;14:4983\u20135000.","journal-title":"Theranostics"},{"key":"1918_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jpp\/rgag076","volume":"78","author":"Y Li","year":"2026","unstructured":"Li Y, Wang X, Wang X, Zhang RS, Zhang Z, Cao XW, et al. Leveraging peptides for targeted protein degradation. J Pharm Pharmacol. 2026;78:rgag076.","journal-title":"J Pharm Pharmacol"},{"key":"1918_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2026.115819","volume":"232","author":"PC Gao","year":"2026","unstructured":"Gao PC, Zhong Y, Luo KX, Jin J. Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation. Adv Drug Deliv Rev. 2026;232:115819.","journal-title":"Adv Drug Deliv Rev"},{"key":"1918_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1021\/acs.bioconjchem.6c00029","volume":"37","author":"XC Lu","year":"2026","unstructured":"Lu XC, Hu QY. Peptide-based PROTACs: transitioning from static paradigm to a dynamic landscape within targeted protein degradation. Bioconjugate Chem. 2026;37:617\u201329.","journal-title":"Bioconjugate Chem"},{"key":"1918_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1505255","volume":"11","author":"JH Shi","year":"2024","unstructured":"Shi JH, Wang L, Zeng XW, Xie CZ, Meng ZW, Campbell A, et al. Precision-engineered PROTACs minimize off-tissue effects in cancer therapy. Front Mol Biosci. 2024;11:1505255.","journal-title":"Front Mol Biosci"},{"key":"1918_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64426-7","volume":"16","author":"RH Zhou","year":"2025","unstructured":"Zhou RH, Wang HF, Zhang GM, Liu YW, Liu XL, Li ZF, et al. Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression. Nat Commun. 2025;16:9374.","journal-title":"Nat Commun"},{"key":"1918_CR20","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1073\/pnas.1920251117","volume":"117","author":"S Lim","year":"2020","unstructured":"Lim S, Khoo R, Peh KM, Teo J, Chang SC, Ng S, et al. bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA). Proc Natl Acad Sci USA. 2020;117:5791\u2013800.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1918_CR21","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1021\/acssynbio.4c00109","volume":"13","author":"MS Kim","year":"2024","unstructured":"Kim MS, Bhargava HK, Shavey GE, Lim WA, El-Samad H, Ng AH. Degron-based bioPROTACs for controlling signaling in CAR T cells. Acs Synth Biol. 2024;13:2313\u201327.","journal-title":"Acs Synth Biol"},{"key":"1918_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50235-x","volume":"15","author":"A Chan","year":"2024","unstructured":"Chan A, Haley RM, Najar MA, Gonzalez-Martinez D, Bugaj LJ, Burslem GM, et al. Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins. Nat Commun. 2024;15:5808.","journal-title":"Nat Commun"},{"key":"1918_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116602","volume":"44","author":"E Kirkiz","year":"2025","unstructured":"Kirkiz E, Kaufmann G, Bergqvist S, Fern\u00e1ndez-Pernas P, Eder T, Quell L, et al. Harnessing the E3 ligase SPOP for targeted degradation of the NUP98::KDM5A fusion oncoprotein. Cell Rep. 2025;44:116602.","journal-title":"Cell Rep"},{"key":"1918_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65481-w","volume":"16","author":"CG Chisholm","year":"2025","unstructured":"Chisholm CG, Bartlett R, Brown ML, Proctor EJ, Farrawell NE, Gorman J, et al. Development of a targeted BioPROTAC degrader selective for misfolded SOD1. Nat Commun. 2025;16:9713.","journal-title":"Nat Commun"},{"key":"1918_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04348-8","volume":"24","author":"S Su","year":"2026","unstructured":"Su S, Sun M, Wang H, Tang Y-D, Chen J, Shi X, et al. Nanobody-based bioPROTAC for viral protein degradation provides an antiviral strategy for porcine arterivirus. J Nanobiotechnol. 2026;24:454.","journal-title":"J Nanobiotechnol"},{"key":"1918_CR26","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li K, Crews CM. PROTACs: past, present and future. Chem Soc Rev. 2022;51:5214\u201336.","journal-title":"Chem Soc Rev"},{"key":"1918_CR27","doi-asserted-by":"publisher","unstructured":"Lim S, Khoo R, Juang Y-C, Gopal P, Zhang H, Yeo C, et al. bioPROTACs establish RAS as a degradable target and provide novel RAS biology insights. Preprint at https:\/\/doi.org\/10.1101\/2020.06.26.174565 2020.","DOI":"10.1101\/2020.06.26.174565"},{"key":"1918_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2022.08.012","volume":"34","author":"JP Wang","year":"2023","unstructured":"Wang JP, Zhang M, Liu SS, He ZP, Wang R, Liang MC, et al. Targeting UBE2C for degradation by bioPROTACs based on bacterial E3 ligase. Chin Chem Lett. 2023;34:107732.","journal-title":"Chin Chem Lett"},{"key":"1918_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s42003-025-08352-w","volume":"8","author":"D Winkelvoss","year":"2025","unstructured":"Winkelvoss D, Vukovic D, H\u00e4nny AC, Riermeier L, Udovcic A, Kolibius J, et al. Molecular features defining the efficiency of bioPROTACs. Commun Biol. 2025;8:946.","journal-title":"Commun Biol"},{"key":"1918_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107616","volume":"300","author":"M Hoffman","year":"2024","unstructured":"Hoffman M, Krum D, Wittrup KD. Bivalent target-binding bioPROTACs induce potent degradation of oncogenic SHP2. J Biol Chem. 2024;300:107616.","journal-title":"J Biol Chem"},{"key":"1918_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105381","volume":"299","author":"D VanDyke","year":"2023","unstructured":"VanDyke D, Xu LD, Sargunas PR, Gilbreth RN, Baca M, Gao CS, et al. Redirecting the specificity of tripartite motif-containing-21 scaffolds using a novel discovery and design approach. J Biol Chem. 2023;299:105381.","journal-title":"J Biol Chem"},{"key":"1918_CR32","doi-asserted-by":"publisher","unstructured":"Yang J, Sun J, Zhu J, Du Y, Tan Y, Wei L, et al. Circular mRNA encoded PROTAC (RiboPROTAC) as a new platform for the degradation of intracellular therapeutic targets. Preprint at bioRxiv 2022. https:\/\/doi.org\/10.1101\/2022.04.22.489232.","DOI":"10.1101\/2022.04.22.489232"},{"key":"1918_CR33","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.chembiol.2022.10.005","volume":"29","author":"SC Chang","year":"2022","unstructured":"Chang SC, Gopal P, Lim S, Wei XA, Chandramohan A, Mangadu R, et al. Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death. Cell Chem Biol. 2022;29:1601\u20131615.e7.","journal-title":"Cell Chem Biol"},{"key":"1918_CR34","doi-asserted-by":"publisher","unstructured":"O\u2019Shea CM, Wright GSA. A biological PROTAC for \u03b1-synuclein. Preprint at bioRxiv 2025. https:\/\/doi.org\/10.1101\/2025.11.13.687972.","DOI":"10.1101\/2025.11.13.687972"},{"key":"1918_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42546-2","volume":"14","author":"A Fletcher","year":"2023","unstructured":"Fletcher A, Clift D, de Vries E, Cuesta SM, Malcolm T, Meghini F, et al. A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation. Nat Commun. 2023;14:7093.","journal-title":"Nat Commun"},{"key":"1918_CR36","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s42003-024-06803-4","volume":"7","author":"JD Taylor","year":"2024","unstructured":"Taylor JD, Barrett N, Cuesta SM, Cassidy K, Pachl F, Dodgson J, et al. Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes. Commun Biol. 2024;7:1179.","journal-title":"Commun Biol"},{"key":"1918_CR37","doi-asserted-by":"publisher","unstructured":"Peche VS, Kenny S, Kang TG, Coventry B, Mi T, Goreshnik I, et al. Reprogramming CAR T-cells with designed bioPROTACs. Preprint at bioRxiv; 2026. https:\/\/doi.org\/10.64898\/2026.02.21.706835.","DOI":"10.64898\/2026.02.21.706835"},{"key":"1918_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201077","volume":"33","author":"S Inano","year":"2025","unstructured":"Inano S, Takaori-Kondo A, Nakajima T. Targeted degradation of KRAS and induction of bystander effects by a modular bioPROTAC. Mol Ther Oncol. 2025;33:201077.","journal-title":"Mol Ther Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01918-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01918-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01918-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:30:17Z","timestamp":1788319817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01918-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":38,"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01918-2","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}